Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Concentra Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Theseus Pharmaceuticals Announces Closing of Tender Offer
Details : Concentra acquires THE-349, an EGFR inhibitor designed to target resistance mutations, for non-small cell lung cancer.
Product Name : THE-349
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 14, 2024
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Concentra Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Concentra Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through th acquisition, Concentra expand its portfolio by gaining Theseus' pipeline, including THE-349, a fourth-generation, selective epidermal growth factor receptor inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment ...
Product Name : THE-349
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 21, 2023
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Concentra Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : THE-630
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THE-630 is a pan-variant tyrosine kinase inhibitor (TKI) of the receptor tyrosine kinase KIT, designed for patients with GIST that have developed resistance to earlier lines of therapy.
Product Name : THE-630
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : THE-630
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : THE-630
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THE-630 is a pan-variant tyrosine kinase inhibitor (TKI) of the receptor tyrosine kinase KIT, designed for patients with GIST that have developed resistance to earlier lines of therapy.
Product Name : THE-630
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : THE-630
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Theseus pharmaceutical introduced its third development program, a pan-variant tyrosine kinase inhibitor (TKI) targeting BCR-ABL for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THE-349 demonstrates brain-penetrability and exhibits substantial CNS activity, which is necessary to address the relatively common recurrence of NSCLC in the brain.
Product Name : THE-349
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2022
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The preclinical data presented at AACR demonstrates that pan-variant EGFR inhibition of all major single-, double-, and triple-mutants, including T790M and C797S, with selectivity over wild-type, is achievable with a single molecule.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 04, 2022
Details : The presentation will detail the characterization of compounds that inhibit the kinase activity, both in vitro and in vivo, of single, double, and triple mutant EGFR variants including T790M and C797S, with selectivity over wild-type EGFR and the ability...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : THE-349 is fourth-generation, potent and selective, small molecule designed to address treatment resistance to existing EGFR inhibitors by targeting common activating mutations in exons 19 and 21 alone or in combination with the most frequently observed ...
Product Name : THE-349
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2022
Lead Product(s) : THE-349
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : THE-630
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy.
Product Name : THE-630
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2022
Lead Product(s) : THE-630
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable